Stay updated on Bemcentinib in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Bemcentinib in AML/MDS Clinical Trial page.

Latest updates to the Bemcentinib in AML/MDS Clinical Trial page
- Check4 days agoChange DetectedThe page has removed a citation regarding the revised recommendations of the International Working Group for Diagnosis and Treatment Outcomes in Acute Myeloid Leukemia, which is a significant loss of core content.SummaryDifference0.7%
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.4%
- Check19 days agoChange DetectedDifference0.4%
- Check26 days agoChange DetectedThe webpage has undergone significant content removal, particularly regarding a Phase Ib/II study of bemcentinib (BGB324) for treating Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS), including detailed study protocols and inclusion/exclusion criteria. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference28%
- Check33 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and removed a date of March 25, 2025, while adding a new date of December 19, 2024.SummaryDifference0.9%
- Check41 days agoChange DetectedThe page has been updated to reflect a new revision version (v2.14.3) and a new results posting date of March 25, 2025, replacing the previous estimated dates and version. This indicates a significant update in the content's accuracy and relevance.SummaryDifference0.6%
Stay in the know with updates to Bemcentinib in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bemcentinib in AML/MDS Clinical Trial page.